Mark Townsend, MD
Psychiatry · Austin, TXNPI 1497778351
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 32.6% of the total. Reporting peaked in 2019 at $593 and has fallen 87.4% since, to $75 in 2022.
Across 71 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$358
- Johnson & Johnson$224
- Sunovion Pharmaceuticals Inc.$151
- Otsuka America Pharmaceutical, Inc.$70
- Lundbeck LLC$70
- Teva Pharmaceuticals USA, Inc.$64
- plus $161 from 5 others
What the payments were for
- Food & beverage$1,097100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $358 |
| Johnson & Johnson | 12 | $224 |
| Sunovion Pharmaceuticals Inc. | 13 | $151 |
| Otsuka America Pharmaceutical, Inc. | 4 | $70 |
| Lundbeck LLC | 4 | $70 |
| Teva Pharmaceuticals USA, Inc. | 3 | $64 |
| Alkermes, Inc. | 2 | $45 |
| Shire North American Group Inc | 2 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $12 |
How this compares
$1,097 in reported general payments places this provider in the 70th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 12 | $952 |
| Quetiapine Fumarate | 30 | $800 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $582 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $299 |
| Bupropion XlBupropion Hcl | 14 | $179 |
| Sertraline Hcl | 19 | $174 |
| Clonazepam | 17 | $148 |
| Duloxetine Hcl | 12 | $146 |
| Escitalopram Oxalate | 29 | $145 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Austin
- Arvinder Pal WaliaAustin$2.5M
- Charles NemeroffAustin$429K
- Divyansu PatelAustin$50K
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.